Regulatory Fragmentation in Nutraceuticals and Herbals: Implications for Safety, Quality Control, and Raw Material Standardisation
Abstract
The worldwide demand for nutraceuticals and herbal products has grown rapidly due to their growing role in health promotion and disease prevention. Despite their widespread use, regulatory approaches differ substantially among countries, leading to inconsistencies in product quality, safety evaluation, and international commercialization. This review examines and compares the regulatory systems of the United States, the European Union, India, Japan, China, Canada, and Australia, with particular attention to product classification, marketing authorization, quality assurance, raw material standardisation, and post-market monitoring. Evidence from published reports was also assessed to identify the consequences of regulatory gaps. The analysis indicates that differences in regulatory expectations contribute to problems such as adulteration, contamination, incorrect botanical identification, and inconsistent product performance. Well-documented incidents, including Aristolochia-induced nephropathy, cardiovascular events linked to Ephedra-containing products, liver injury associated with Hydroxycut, and heavy metal contamination in certain Ayurvedic preparations, demonstrate the potential health risks arising from inadequate regulatory control. The findings emphasize the need for greater international alignment of regulatory practices, stronger standards for raw material quality, improved surveillance throughout the product lifecycle, and the adoption of emerging technologies such as artificial intelligence to strengthen regulatory decision-making while accommodating country-specific regulatory frameworks